A Compendium of Nuclear Receptors: The Superfamily of Ligand-Modulated Transcription Factors

A. K. Dash, R. Tyagi
{"title":"A Compendium of Nuclear Receptors: The Superfamily of Ligand-Modulated Transcription Factors","authors":"A. K. Dash, R. Tyagi","doi":"10.18519/JER/2016/V20/149824","DOIUrl":null,"url":null,"abstract":"The ‘Nuclear Receptor Super-family’ is a group of ligand-modulated transcription factors with 48 members identified in human genome. Members of this family of receptors are now established to be involved in regulation of a plethora of physiological processes in the paradigms of development, reproduction, metabolism and homeostasis. Also, in the myriads of patho-physiological processes, these receptors have consistently exhibited enormous potential as targets for the treatment of diseases such as cancers, osteoporosis, diabetes, obesity, coronary heart disease, asthma, hypertension, thyroid conditions and multiple other metabolic disorders. In recent times, it is estimated that about 15% of the clinical drugs, used in treatments of different ailments, target nuclear receptors. These receptors include steroid/thyroid hormone receptors and orphan/adopted receptors that function as intra-cellular transcription factors to regulate expression of several hundreds of genes in response to their cognate ligands. Interestingly, nuclear receptors are also being assigned a novel role in serving as ‘epigenetic marks’ for the retention and transmission of cellular ‘transcriptional memory’. These receptors function primarily either as homodimers or heterodimers with Retinoid X Receptor (RXR) or sometimes as monomers. Being ‘drug responsive’ these receptors offer attractive targets for drug discovery since their activities can be favorably modulated by interacting ligands. However, many of the newly discovered members of this family of receptors remain incompletely understood, both in terms of physiological roles and activating ligands. In brief, nuclear receptors represent enormous potential for drug discovery and are continuously being examined to unravel the mysteries underlying their mechanisms of action. It has been well-over three decades since the cloning of steroid/nuclear receptors in the 1980s. Therefore, it’s only appropriate to prepare a comprehensive review that provides a compendium of facts and events from receptor cloning and characterization to establishment of receptor domain structures, physiological functioning and consequences of receptor malfunctioning. This review is expected to serve as a refreshing compendium of nuclear receptors for both, the beginners, as well as experts working in the areas of nuclear receptor biology.","PeriodicalId":15664,"journal":{"name":"Journal of Endocrinology and Reproduction","volume":"16 1","pages":"1-27"},"PeriodicalIF":0.0000,"publicationDate":"2016-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endocrinology and Reproduction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18519/JER/2016/V20/149824","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

The ‘Nuclear Receptor Super-family’ is a group of ligand-modulated transcription factors with 48 members identified in human genome. Members of this family of receptors are now established to be involved in regulation of a plethora of physiological processes in the paradigms of development, reproduction, metabolism and homeostasis. Also, in the myriads of patho-physiological processes, these receptors have consistently exhibited enormous potential as targets for the treatment of diseases such as cancers, osteoporosis, diabetes, obesity, coronary heart disease, asthma, hypertension, thyroid conditions and multiple other metabolic disorders. In recent times, it is estimated that about 15% of the clinical drugs, used in treatments of different ailments, target nuclear receptors. These receptors include steroid/thyroid hormone receptors and orphan/adopted receptors that function as intra-cellular transcription factors to regulate expression of several hundreds of genes in response to their cognate ligands. Interestingly, nuclear receptors are also being assigned a novel role in serving as ‘epigenetic marks’ for the retention and transmission of cellular ‘transcriptional memory’. These receptors function primarily either as homodimers or heterodimers with Retinoid X Receptor (RXR) or sometimes as monomers. Being ‘drug responsive’ these receptors offer attractive targets for drug discovery since their activities can be favorably modulated by interacting ligands. However, many of the newly discovered members of this family of receptors remain incompletely understood, both in terms of physiological roles and activating ligands. In brief, nuclear receptors represent enormous potential for drug discovery and are continuously being examined to unravel the mysteries underlying their mechanisms of action. It has been well-over three decades since the cloning of steroid/nuclear receptors in the 1980s. Therefore, it’s only appropriate to prepare a comprehensive review that provides a compendium of facts and events from receptor cloning and characterization to establishment of receptor domain structures, physiological functioning and consequences of receptor malfunctioning. This review is expected to serve as a refreshing compendium of nuclear receptors for both, the beginners, as well as experts working in the areas of nuclear receptor biology.
核受体简编:配体调节转录因子超家族
“核受体超家族”是一组配体调节的转录因子,在人类基因组中有48个成员。这一受体家族的成员现在被确定参与了发育、繁殖、代谢和体内平衡等多种生理过程的调节。此外,在无数的病理生理过程中,这些受体一直表现出巨大的潜力,作为治疗癌症、骨质疏松症、糖尿病、肥胖、冠心病、哮喘、高血压、甲状腺疾病和多种其他代谢紊乱等疾病的靶点。近年来,据估计,用于治疗不同疾病的临床药物中约有15%是针对核受体的。这些受体包括类固醇/甲状腺激素受体和孤儿/收养受体,它们作为细胞内转录因子调节数百种基因的表达,以响应其同源配体。有趣的是,核受体也被赋予了一个新的角色,作为细胞“转录记忆”的保留和传递的“表观遗传标记”。这些受体主要与类视黄醇X受体(RXR)作为同二聚体或异二聚体起作用,有时也作为单体起作用。作为“药物反应性”,这些受体为药物发现提供了有吸引力的靶标,因为它们的活性可以通过相互作用的配体进行有利的调节。然而,许多新发现的受体家族成员在生理作用和激活配体方面仍未完全了解。简而言之,核受体代表着巨大的药物发现潜力,并不断被研究以揭示其作用机制的奥秘。自20世纪80年代克隆类固醇/核受体以来,已经有30多年了。因此,只有准备一份全面的综述,提供从受体克隆和表征到受体结构域的建立,生理功能和受体功能障碍的后果的事实和事件的概要。这篇综述有望为核受体生物学的初学者和专家提供一个令人耳目一新的核受体纲要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信